Skip to content

Addition of epinephrine spoils anti-pruritic effect of butorphanol against epidural morphine

Addition of epinephrine spoils anti-pruritic effect of butorphanol against epidural morphine - Co-use of epinephrine and butorphanol

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009001
Enrollment
95
Registered
2012-09-28
Start date
2007-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological open surgery

Interventions

control group was set as patients who received postoperative epidural infusion (2ml/hour) of 0.2% ropivacaine 100ml containing morphine 6 mg and butorphanol 2 mg with no epinephrine. E0.15 group was s

Sponsors

Japanese Red Cross Society Wakayama Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: ASA physical status 1-2

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if one or more of the following criteria were met: allergy to opioids, concurrent use of antidepressants or analgesics, smoking habit, medical histories of chronic inflammatory disease and motion sickness, severe obesity (BMI > 25), contraindications to epidural catheterization such as infection, anatomical abnormalities of the spine, or full anticoagulation.

Design outcomes

Primary

MeasureTime frame
Primary endpoint was the incidence of pruritus during the postoperative 24 hours.

Secondary

MeasureTime frame
The following measures were selected at the secondary endpoint: incidences of dizziness, incidences of postoperative emesis (none, nausea, retching, and vomiting), intensities of postoperative wound pain: Visual analogue scales (VAS, mm: 0 = no pain, 100 = worst pain imaginable, at rest and at coughing), and incidences of side effects.

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026